ArticlePediatric cardiology2026
The hemodynamic effects of sacubitril/valsartan in the first 24 h of initiation in pediatric cardiac intensive care unit patients: insights using high-fidelity data.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sacubitril/valsartan is increasingly used in pediatric cardiac patients, though its acute physiologic effects in critically ill children remain incompletely characterized. We sought to define the early hemodynamic and tissue-level response to sacubitril/valsartan using high-fidelity physiologic data. This was a retrospective study of children in a cardiac intensive care unit with continuous physiologic monitoring. High-resolution data were temporally aligned to the time of sacubitril/valsartan initiation. Locally weighted regression was used to characterize percent change in physiologic variables relative to baseline. Linear mixed effects models were used to estimate post-initiation trends in absolute units from 2 to 24 h, accounting for repeated measures within patients and adjusting for age, ventricular assist device status, milrinone exposure, and circulatory physiology. Unsupervised clustering using Ward linkage was performed on percent change features to assess heterogeneity in response. Fifty-nine patients were included in the final analyses. Following sacubitril/valsartan initiation, heart rate and systolic blood pressure decreased while diastolic and mean arterial pressure increased. Central venous pressure rose over time. Measures of systemic oxygen delivery improved, including pulse oximetry and renal near-infrared spectroscopy (NIRS), with the largest effect observed in renal NIRS. These changes were consistent across models and remained significant after adjustment. Clustering identified two response patterns, reflecting differences in magnitude rather than distinct physiologic phenotypes. Sacubitril/valsartan initiation in critically ill children is associated with coordinated changes in arterial, venous, and tissue-level physiology consistent with improved systemic oxygen delivery. The response appears continuous, with variability in magnitude across patients rather than discrete phenotypes.
Identifiers
42782309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.